Research on the Impact of Intelligent Production on the Quality Consistency of Blood Diagnostic Reagents —Taking Anti-A and Anti-B Reagents as Examples

This study explores the impact of intelligent production on the quality consistency of anti-A and anti-B reagents. Through standardized production processes, real-time quality monitoring, and data analysis systems, intelligent technology reduced the inter-batch variation in agglutination strength from 1.5 levels to 0.2 levels, and the comprehensive error rate decreased by 85.2%. The study analyzed the implementation difficulties and adaptation strategies, and proposed innovative industry standards and multi-party collaboration solutions. Intelligent production not only improved the stability of reagent quality but also provided a reliable guarantee for blood type identification safety, which has significant implications for promoting the advancement of blood diagnostic technology.